1.By using chimeric antigen receptor T cell(CAR-T)bridging allogeneic hematopoietic stem cell transplantation(allo-HSCT)and targeted tyrosine kinase inhibitor(TKI)maintenance therapy,Dr.Song Yanzhi has increased the 2-year overall survival(OS)and disease-free survival(LFS)rates of R/R Ph+B-ALL patients to 79%.

2.Aiming at the popular target of blood tumors-CD38,Dr.Li Zhihui explored in refractory/recurrent children with hematologic malignancies that recurred after allo-HSCT,and confirmed that the treatment regimen containing CD38 monoclonal antibody-Daretuzumab showed initial therapeutic feasibility and effectiveness for half of CD38-positive patients.